Brief: Aptose Reports Complete Response Data From Ongoing Aptivate International Phase 1/2 Study Of Tuspetinib
09/12/2023 23:53
Dec 9 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE - REPORTING COMPLETE RESPONSE DATA FROM ONGOING
APTIVATE
INTERNATIONAL PHASE 1/2 STUDY OF TUSPETINIB (TUS) IN
RELAPSED/REFRACTORY AML PATIENTS
Source text for Eikon: ID:nGNX9g9ZyF
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting